You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

~ Buy the ANGELIQ (drospirenone; estradiol) Drug Profile, 2024 PDF Report in the Report Store ~

ANGELIQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Angeliq, and what generic alternatives are available?

Angeliq is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has twenty-one patent family members in sixteen countries.

The generic ingredient in ANGELIQ is drospirenone; estradiol. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone; estradiol profile page.

DrugPatentWatch® Generic Entry Outlook for Angeliq

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 22, 2031. This may change due to patent challenges or generic licensing.

There are two Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for ANGELIQ
Drug patent expirations by year for ANGELIQ
Drug Prices for ANGELIQ

See drug prices for ANGELIQ

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ANGELIQ
Generic Entry Date for ANGELIQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ANGELIQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brigham and Women's HospitalPhase 4
Bayer
BayerPhase 2

See all ANGELIQ clinical trials

Pharmacology for ANGELIQ
Drug ClassEstrogen
Progestin
Mechanism of ActionEstrogen Receptor Agonists
Paragraph IV (Patent) Challenges for ANGELIQ
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ANGELIQ Tablets drospirenone; estradiol 0.25 mg/0.5 mg 021355 1 2015-01-08
ANGELIQ Tablets drospirenone; estradiol 0.5 mg/1 mg 021355 1 2007-12-26

US Patents and Regulatory Information for ANGELIQ

ANGELIQ is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ANGELIQ is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ANGELIQ

Very low-dosed solid oral dosage forms for HRT
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare ANGELIQ drospirenone; estradiol TABLET;ORAL 021355-001 Feb 29, 2012 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Bayer Hlthcare ANGELIQ drospirenone; estradiol TABLET;ORAL 021355-002 Sep 28, 2005 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ANGELIQ

When does loss-of-exclusivity occur for ANGELIQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 0912
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 11240102
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2012026115
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 95801
Estimated Expiration: ⤷  Try a Trial

China

Patent: 2985070
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 30107
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 120523
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 6095
Estimated Expiration: ⤷  Try a Trial

Patent: 1201403
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 58063
Estimated Expiration: ⤷  Try a Trial

Guatemala

Patent: 1200281
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 20465
Estimated Expiration: ⤷  Try a Trial

Patent: 13523860
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 6702
Estimated Expiration: ⤷  Try a Trial

Patent: 12012026
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 130097073
Estimated Expiration: ⤷  Try a Trial

Patent: 180018827
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 19300
Estimated Expiration: ⤷  Try a Trial

Patent: 1204368
Estimated Expiration: ⤷  Try a Trial

Uruguay

Patent: 343
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ANGELIQ around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2168974 Procédé de preparation de Drospirenon (6ß, 7ß; 15ß,16ß-diméthylène-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone, DRSP) (Process for the preparation of Drospirenon (6ß, 7ß; 15ß,16ß-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone, DRSP)) ⤷  Try a Trial
Slovakia 283546 ⤷  Try a Trial
Germany 19633685 Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens (Production of drospirenone useful as steroidal agent) ⤷  Try a Trial
Portugal 1149841 ⤷  Try a Trial
Austria 446966 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 9806738 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ANGELIQ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0398460 04C0022 France ⤷  Try a Trial PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
0398460 SPC/GB04/032 United Kingdom ⤷  Try a Trial PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
3632448 LUC00266 Luxembourg ⤷  Try a Trial PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 61678, 20210401
2588114 LUC00227 Luxembourg ⤷  Try a Trial PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022
0918791 PA2006009 Lithuania ⤷  Try a Trial PRODUCT NAME: DROSPIRENONUM; NAT. REGISTRATION NO/DATE: LT/1/06/0520/001, 2006 07 10 LT/1/06/0520/002, 2006 07 10 LT/1/06/0520/003, 2006 07 10 LT/1/06/0520/004 20060710; FIRST REGISTRATION: RVG 31781 20050804
3632448 22C1031 France ⤷  Try a Trial PRODUCT NAME: DROSPIRENONE; NAT. REGISTRATION NO/DATE: NL49691 20191121; FIRST REGISTRATION: DK - 31332 20191016
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.